Therapeutic applications for subcutaneous triptans in the acute treatment of migraine

Current Medical Research and Opinion

Volumn 28, Issue 7, 2012, Pages 1231-1238

  Erlichson, Kathy ^a   Waight, Julie ^b  

^a Mercy Health Research   (United States)

^b Private Practice   (United States)

Author keywords

Injection; Subcutaneous; Sumatriptan; Triptans

Indexed keywords

ALMOTRIPTAN; PLACEBO; SUMATRIPTAN; ZOLMITRIPTAN;

ANALGESIA; CARDIOVASCULAR RISK; COGNITION; DRUG ABSORPTION; DRUG EFFICACY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; INJECTION SITE BURNING; INJECTION SITE STINGING; MENSTRUAL MIGRAINE; MIGRAINE; NAUSEA; NAUSEA AND VOMITING; PATIENT SATISFACTION; PERCEPTION; PHONOPHOBIA; PHOTOPHOBIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; STOMACH PARESIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

HUMANS; INJECTIONS, SUBCUTANEOUS; MIGRAINE DISORDERS; NAUSEA; SUMATRIPTAN; TREATMENT OUTCOME;

EID: 84863630608     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.674501     Document Type: Review

References (49)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57 (Pubitemid 32777747)
2. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd ed. Cephalalgia 2004;24(Suppl 1):9-160
3. Anthony M, Rasmussen BK. Migraine without aura. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds). The Headaches. New York, NY: Raven Press, 1993: 255-61
4. Saxena PR, Ferrari MD. 5HT1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989;10:200-4 (Pubitemid 19158378)
5. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine-new insights. Can J Neurol Sci 1999;26:S12-19
6. Peroutka SJ. The pharmacology of current antimigraine drugs. Headache 1990;30(Suppl 1):5-11
7. Belvis R, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent Pat CNS Drug Discov 2009;4:70-81
8. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58
9. Santanello NC, Davies G, Allen C, et al. Determinants of migraine-specific quality of life. Cephalalgia 2002;22:680-5 (Pubitemid 36609338)
10. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000;75:782-9 (Pubitemid 30640635)
11. Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med 1998;158:1013-18 (Pubitemid 28213579)
12. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000;20:554-60 (Pubitemid 32269473)
13. Lipton RB, Stewart WF. Acute migraine therapy: do doctors know what migraine patients want from therapy? Headache 1999;39(Suppl 2):S20-6 (Pubitemid 30002025)
14. Bouchard J, Cortelli P, Dahlöf C, et al. A multinational investigation of the impact of subcutaneous sumatriptan. IV: Patient satisfaction. Pharmacoeconomics 1997;11(Suppl 1):43-50 (Pubitemid 27286107)
15. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology 2000;55(9 Suppl 2):S29-35
16. Bigal M, Rapoport A, Aurora S, et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache 2007;47: 475-9 (Pubitemid 46625257)
17. Cady RK, Maizels M, Reeves DL, et al. Predictors of adherence to triptans: factors of sustained vs lapsed users. Headache 2009;49:386-94
18. Panconesi A, Pavone E, Franchini M, et al. Triptans: low utilization and high turnover in the general population. Cephalalgia 2010;30:576-81
19. Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009;49:1435-44
20. Sumavel DosePro (sumatriptan injection) for subcutaneous use. Prescribing information. San Diego, CA: Zogenix, Inc., 2011
21. Dahlof C. Update on sumatriptan: new progress in migraine treatment. Future Medicine-Therapy 2005;2:349-56 (Pubitemid 40790193)
22. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Eng J Med 1991;325:316-21
23. Cady RK, Wendt JK, Kirchner JF, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5
24. Salonen R. Drug comparisons: why are they so difficult? Cephalalgia 2000;20(Suppl 2):25-32 (Pubitemid 32127831)
25. Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996;28:171-8
26. Tfelt-Hansen P. Early responses in randomized clinical trials of triptans in acute migraine treatment. Are they clinically relevant? A comment Headache 2010;50:1198-200
27. Farmer K, Cady R, Bleiberg J, et al. A pilot study to measure cognitive efficiency during migraine. Headache 2000;40:657-61
28. Valade D. Early treatment of acute migraine: new evidence of benefits. Cephalalgia 2009;29(Suppl 3):15-21
29. Aurora SK, Barrodale PM, McDonald SA, et al. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache 2009;49:1001-4
30. Linde M, Mellberg A, Dahlöf C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 2006;26:113-21
31. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995;35:387-96
32. National Headache Foundation. Migraine patient survey, April 2010. Available at: http://www.headaches.org/NHF-Programs/NHF-Web-Surveys [Last accessed 27 November 2010]
33. Aurora SK, Kori SH, Barrodale P, et al. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache 2006;46:57-63
34. Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 1975;2:57-63
35. Tokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol 1984;17:67-75 (Pubitemid 14054613)
36. Ekbom K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose-comparison study. Acta Neurol Scand 1993;88:63-9 (Pubitemid 23210979)
37. Bousser MG, D'Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. J Intern Med 1993;234:211-16 (Pubitemid 23244417)
38. Salonen R, Saiers J. Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Cephalalgia 1999;19:16-19 (Pubitemid 29136846)
39. Welch KM, Mathew NT, Stone P, et al. Tolerability of sumatriptan: clinical trials and postmarketing experience. Cephalalgia 2000;20:687-95 (Pubitemid 32127835)
40. Schoenen J. Acute migraine therapy-the newer drugs. Curr Opin Neurol 1997;10:237-43 (Pubitemid 27352978)
41. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004;44:414-25 (Pubitemid 38685549)
42. O'Quinn S, Davis RL, Gutterman DL, et al. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999;19:223-31 (Pubitemid 29268495)
43. Kaniecki RG. Mixing sumatriptan: a prospective study of stratified care using multiple formulations. Headache 2001;41:862-6 (Pubitemid 33043149)
44. Gruffydd-Jones K, Hood CA, Price DB. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia 1997;17:31-6 (Pubitemid 27101418)
45. Gross ML, Kay J, Turner AM, et al. Sumatriptan in acute migraine using a novel cartridge system self-injector. Headache 1994;34:559-63 (Pubitemid 24378704)
46. Mushet GR, Cady RK, Baker CC, et al. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREXSTATdose System. Clin Ther 1996;18:687-99 (Pubitemid 26323046)
47. Cady RK, Aurora SK, Brandes JL, et al. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache 2011;51:1202-11
48. Kilminster SG, Dowson AJ, Tepper SJ, et al. Reliability, validity, and clinical utility of the Migraine-ACT questionnaire. Headache 2006;46:553-62
49. Rothrock JF, Cady RK, Aurora SK, et al. Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Curr Med Res Opin 2011;27:2185-91